BioMarin Pharmaceutical Inc. (BMRN): Price and Financial Metrics

BioMarin Pharmaceutical Inc. (BMRN)

Today's Latest Price: $83.24 USD

2.67 (-3.11%)

Updated Jan 27 4:00pm

Add BMRN to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 488 in Biotech

See all "A" rated Strong Buy stocks

BMRN Stock Summary

  • BMRN has a higher market value than 87.15% of US stocks; more precisely, its current market capitalization is $15,595,213,692.
  • Price to trailing twelve month operating cash flow for BMRN is currently 99.91, higher than 94.61% of US stocks with positive operating cash flow.
  • With a year-over-year growth in debt of 71.7%, Biomarin Pharmaceutical Inc's debt growth rate surpasses 85.78% of about US stocks.
  • Stocks that are quantitatively similar to BMRN, based on their financial statements, market capitalization, and price volatility, are CORT, TCOM, ALRM, JNPR, and FORM.
  • Visit BMRN's SEC page to see the company's official filings. To visit the company's web site, go to

BMRN Stock Price Chart Interactive Chart >

Price chart for BMRN

BMRN Price/Volume Stats

Current price $83.24 52-week high $131.95
Prev. close $85.91 52-week low $68.25
Day low $82.80 Volume 1,136,029
Day high $85.97 Avg. volume 1,696,875
50-day MA $83.01 Dividend yield N/A
200-day MA $93.04 Market Cap 15.11B

BioMarin Pharmaceutical Inc. (BMRN) Company Bio

BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company was founded in 1996 and is based in San Rafael, California.

BMRN Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$83.24$20495.56 23757%

We started the process of determining a valid price forecast for Biomarin Pharmaceutical Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Biomarin Pharmaceutical Inc ranked in the 99th percentile in terms of potential gain offered. As the table below shows, the model suggests the stock is dramatically undervalued -- investors should note, though, that such returns are always unlikely and not to be expected. The most interesting components of our discounted cash flow analysis for Biomarin Pharmaceutical Inc ended up being:

  • Its compound free cash flow growth rate, as measured over the past 0.25 years, is 4.87% -- higher than 97.44% of stocks in our DCF forecasting set.
  • The business' balance sheet suggests that 8% of the company's capital is sourced from debt; this is greater than only 22.66% of the free cash flow producing stocks we're observing.
  • As a business, Biomarin Pharmaceutical Inc experienced a tax rate of about 102% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than 93.88% of stocks generating free cash flow.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as BMRN, try THC, NVAX, KMDA, VRTX, and AMEH.

BMRN Latest News Stream

Event/Time News Detail
Loading, please wait...

BMRN Latest Social Stream

Loading social stream, please wait...

View Full BMRN Social Stream

Latest BMRN News From Around the Web

Below are the latest news stories about Biomarin Pharmaceutical Inc that investors may wish to consider to help them evaluate BMRN as an investment opportunity.

Is Now A Good Time To Buy BioMarin Stock?

Shares in this biotech company are down considerably from where they were this summer, but the stock looks ready to take off again.

Yahoo | January 22, 2021

BIOMARIN INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of BioMarin Pharmaceutical Inc. - BMRN

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into BioMarin Pharmaceutical Inc. (NasdaqGS: BMRN). On August 19, 2020, the Company disclosed that it received a Complete Response Letter (“CRL”) from the FDA rejecting its Biologics License Application (“BLA”) for its product, valoctocogene roxaparvovec, and recommending two years of da

Business Wire | January 15, 2021

Wedbush Stick to Their Buy Rating for BioMarin Pharmaceutical By

Wedbush Stick to Their Buy Rating for BioMarin Pharmaceutical | January 12, 2021

Stock Market News for Jan 12, 2021

Benchmarks declined from record highs on Monday as investors weighed impact of rise in coronavirus cases and ongoing political turmoil on economic growth.

Yahoo | January 12, 2021

Covid-19 Impact On Cell and Gene Therapy Market Next Big Thing | Major Giants: Amgen, Biogen, BioMarin Pharmaceuticals, Bristol-Myers Squibb Company, GlaxoSmithKline, Novartis, Pfize

COHERENT MARKET INSIGHTS has added a new report titled Global Cell and Gene Therapy Market with analysis provides the insights which bring marketplace clearly into the focus and thus help organizations make better decisions. This Cell and Gene Therapy Market

OpenPR | January 11, 2021

Read More 'BMRN' Stories Here

BMRN Price Returns

1-mo -4.96%
3-mo 11.85%
6-mo -30.52%
1-year -3.09%
3-year -9.13%
5-year 12.46%
YTD -5.07%
2020 3.71%
2019 -0.70%
2018 -4.51%
2017 7.64%
2016 -20.92%

Continue Researching BMRN

Here are a few links from around the web to help you further your research on Biomarin Pharmaceutical Inc's stock as an investment opportunity:

Biomarin Pharmaceutical Inc (BMRN) Stock Price | Nasdaq
Biomarin Pharmaceutical Inc (BMRN) Stock Quote, History and News - Yahoo Finance
Biomarin Pharmaceutical Inc (BMRN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8592 seconds.